Search Results
Apr 01, 2026, 06:01 ET SIDUS SPACE REPORTS FULL-YEAR 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES
solutions, including satellite manufacturing and technology integration, AI-driven space-based data solutions, mission planning and management operations, AI/ML products and services, and space and defense hardware manufacturing. With its mission of Space Access Reimagined®, Sidus Space is committed to rapid
More news about: Sidus Space, Inc.
Mar 31, 2026, 16:45 ET Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
the Phase 3 study DAYBREAK to evaluate its efficacy and safety in wet AMD. DAYBREAK has completed enrollment. DAYBREAK uses KSI-501's enhanced 50 mg/mL formulation containing both conjugated and unconjugated antibody that is intended to balance immediacy and durability. Topline data for the one-year
More news about: Kodiak Sciences Inc.
Mar 31, 2026, 16:03 ET PrismML Launches World's First 1-Bit AI Model to Redefine Intelligence at the Edge
systems that can both operate efficiently at the edge and scale economically in the cloud."Bill Jia, VP of Engineering at Google, Core ML/AI, added: "When advanced models can run on constrained devices, it reshapes system design end to end. Efficiency at the model level compounds across infrastructure."PrismML's
More news about: PrismML
Mar 31, 2026, 14:08 ET Fever-Tree Expands Pineapple Ginger Beer and Mojito Mix Availability Nationwide
tropical pineapple and finished with a hint of Mexican lime, it's the perfect companion for rum, vodka, tequila or a non-alcoholic spirit.Sold in 200 ml glass bottle four-packs, Pineapple Ginger Beer builds on Fever-Tree's beloved ginger beer portfolio that has become the 3#1 ginger beer by
More news about: Molson Coors Beverage Company
Mar 31, 2026, 11:11 ET New FDA Plausible Mechanism Framework Spurs Development of Personalized In Vivo Prime Editing Platform for Urea Cycle Disorders
Kiran Musunuru, MD, PhD, MPH, ML, MRA, Co-Director of the
More news about: Children's Hospital of Philadelphia
Mar 31, 2026, 11:00 ET Alltrna Announces Approval to Initiate First-in-Human Clinical Trial of AP003, the First tRNA Therapeutic to Enter Clinical Trials
of the full-length protein.About AlltrnaAlltrna unlocks tRNA biology to treat disease. The company's platform incorporates AI/ML tools to develop and deliver diverse programmable molecules with broad therapeutic potential. Alltrna has an unprecedented opportunity to advance a single
More news about: Alltrna
Mar 31, 2026, 10:01 ET Angel's Envy Debuts 2026 Cask Strength Dual Release Featuring Annual Bourbon and First-Ever Age-Stated Rye
retail price of $249.99 per 750ml bottle, with approximately 20,640 bottles released nationwide and an additional 1,446 bottles available internationally. The Angel's Envy 10-Year Cask Strength Rye will be offered at a suggested retail price of $269.99 per 750ml bottle and will be more limited,
More news about: Angel's Envy
Mar 31, 2026, 09:11 ET Lupin Receives Tentative Approval from U.S. FDA for Sugammadex Injection
United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vial.
More news about: Lupin Pharmaceuticals, Inc.
Mar 31, 2026, 09:04 ET The World's Largest BuzzBallz Has Arrived: Meet the 10-foot Pink Lemonsqueezy One Night Lemonade Stand
first-served basis.BuzzBallz's new Pink Lemonsqueezy cocktail is available now at retailers nationwide and online. Clocking in at 15% ABV in a 200 mL size, it delivers a bright pink lemonade flavor with a hint of berry-like sweetness that matches the brand's bold, playful personality.For all
More news about: BuzzBallz
Mar 31, 2026, 09:00 ET KNOB CREEK® DEBUTS BLENDER'S EDITION, A LIMITED SERIES CELEBRATING THE ART OF BLENDING
Blender's Edition 01 is aged a minimum of 10 years and bottled at 106 proof, now available nationwide at a suggested retail price of $44.99 for a 750mL bottle."The Blender's Edition series is about slowing down and discovering the story each blend tells—with a unique and new experience in each
More news about: Suntory Global Spirits
Mar 31, 2026, 08:58 ET Co-PSMA data published in the European Urology journal
[4] in BCR where any SOC imaging agent could have been used and participant selection criteria had no limitation on upper PSA levels (median 0.9 ng/mL, range 0.25 – 17.6), to this head-to-head Co-PSMA trial against 68Ga-PSMA-11 in BCR patients with low PSA (median 0.43, IQR: 0.31– 0.63).
More news about: Clarity Pharmaceuticals
Mar 31, 2026, 08:00 ET Oracle Unveils AI Data Platform for US Federal Government
situational awareness and operational decision support.The platform supports open ecosystem compatibility with Python, Spark, open-source AI/ML frameworks, and existing agency tools—ensuring agencies can leverage their current investments while adopting next-generation AI capabilities.Built
More news about: Oracle Corporation
Mar 30, 2026, 17:40 ET BTQ Technologies Provides Full-Year 2025 Corporate Update Highlighting Commercial Progress Across QCIM, QPerfect, QSSN and Bitcoin Quantum
initial design wins, with development boards expected to debut in Q3 2026. ASIC IP performance estimates are expected in Q2 2026 for ML-KEM, ML-DSA, SHA-3, and AES workloads. The Company's current roadmap contemplates silicon-proven ASIC IP availability in the first half of 2027
More news about: BTQ Technologies Corp.
Mar 30, 2026, 09:35 ET Hengrui Pharma and Braveheart Bio Announce Positive Phase 2 Results with HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy
improvements in key secondary and exploratory measures in Group 2, the dose selected for open-label extension (OLE), including increase in pVO2 of 1.0 mL/kg/min, KCCQ-CSS of 10.5 points, and reduction in NT-proBNP of 88%. All 42 patients enrolled in the OLE part of the study and continued to receive
More news about: Braveheart Bio
Mar 30, 2026, 07:30 ET Neurolief Secures Additional $6 Million Investment Following FDA Approval of Proliv™Rx, Expanding Access to Brain Neuromodulation Therapy for Patients with Inadequate Response to Antidepressants
ng-fda-approval-of-prolivrx-expanding-access-to-brain-neuromodulation-therapy-for-patients-with-inadequate-response-to-antidepressants-302728179.html
More news about: Neurolief Inc.
Mar 30, 2026, 06:29 ET gateretail and JK Tech Partner to Advance AI-Powered Inflight Retail Intelligence
pricing recommendations, and supplier order automation within a single, integrated planning environment. By leveraging trusted enterprise data, advanced AI/ML models, and agentic workflows, airlines can shift from fragmented, reactive processes to predictive, coordinated execution.Key benefits include
More news about: JK Tech
Mar 30, 2026, 06:23 ET gateretail and JK Tech Partner to Advance AI-Powered Inflight Retail Intelligence
pricing recommendations, and supplier order automation within a single, integrated planning environment. By leveraging trusted enterprise data, advanced AI/ML models, and agentic workflows, airlines can shift from fragmented, reactive processes to predictive, coordinated execution.Key benefits include
More news about: JK Tech
Mar 30, 2026, 06:14 ET gateretail and JK Tech Partner to Advance AI-Powered Inflight Retail Intelligence
pricing recommendations, and supplier order automation within a single, integrated planning environment. By leveraging trusted enterprise data, advanced AI/ML models, and agentic workflows, airlines can shift from fragmented, reactive processes to predictive, coordinated execution.Key benefits include
More news about: JK Tech
Mar 30, 2026, 06:05 ET gateretail and JK Tech Partner to Advance AI-Powered Inflight Retail Intelligence
pricing recommendations, and supplier order automation within a single, integrated planning environment. By leveraging trusted enterprise data, advanced AI/ML models, and agentic workflows, airlines can shift from fragmented, reactive processes to predictive, coordinated execution.Key benefits include
More news about: JK Tech
Mar 28, 2026, 16:45 ET REPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS
Pronounced Low-Density Lipoprotein Cholesterol Lowering: The Gift That Keeps Giving. Circulation. 2022;146(15):1120-1122. Rao SV, O'Donoghue ML, Ruel M, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College
More news about: Amgen
Mar 28, 2026, 15:15 ET Phase 3b data presented at AAD Annual Meeting show Lilly's Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity
prepare and give Taltz injections to your child.Learn moreTaltz is a prescription medicine available as a 80 mg/mL, 40 mg/0.5mL, 20 mg/0.25mL injection. For more information, call 1-800-545-5979 or go to
More news about: Eli Lilly and Company
Mar 27, 2026, 16:12 ET Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update
survival was 21.3 monthsIn an exploratory analysis comparing patients receiving INT230-6 at a total dose (in mL) that treated greater than 40% of the patient's total tumor burden ("TTB") compared to those treated with less than 40% of their TTB, the:Disease
More news about: Intensity Therapeutics Inc.
Mar 27, 2026, 10:00 ET AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting
healthcare provider tells you to use it.SKYRIZI (risankizumab-rzaa) is available in a 150 mg/mL prefilled syringe and pen, a 600 mg/10 mL vial for intravenous infusion, and a 180 mg/1.2 mL or 360 mg/2.4 mL single-dose prefilled cartridge with on-body injector.About RINVOQ®
More news about: AbbVie
Mar 27, 2026, 09:30 ET How Decentralized AI is Unlocking Value in Cardiac Diagnostics
next-generation scanner's advanced multi-directional DWI sequence achieving 100% sensitivity and 100% specificity for clinically relevant lesions greater than 1.0 mL, detecting strokes as small as 2.8 mm while cutting scan time by approximately 30%. The prospective multi-center study across Massachusetts General Hospital,
More news about: USA News Group
Mar 27, 2026, 09:00 ET Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis
pounds (40 kg) with moderate-to-severe atopic dermatitis that is not well controlled with topical prescription therapies.8 EBGLYSS 250 mg/2 mL injection is dosed as a single monthly maintenance injection following the initial phase of treatment. The recommended initial starting dose of EBGLYSS
More news about: Eli Lilly and Company